Medication info

BM Heparin Sodium Injection 25000 units

Prescription medicationIntravenous injection · Subcutaneous injection
Ingredient · strength
Heparin Sodium›Strength being verified
Manufacturer / importer
BM Co., Ltd.
Appearance
A transparent liquid that is colorless or pale yellow, contained in a brown vial
Packaging
5mL/vial X 10 vials
Approval status
Active

MFDS item code 201207633 · Notified 2012.11.02 · Insurance code 654802091

Summary

Main use
Prevention and treatment of thrombotic and embolic diseases; diagnosis and treatment of coagulation disorders; inhibition of blood coagulation
Who receives it
Adults
Adult administration
Usually administered by intravenous injection or added to the perfusate during extracorporeal circulation. The effect occurs immediately after administration, but heparin sensitivity varies considerably among individuals. Therefore, perform a heparin sensitivity test before administration and measure blood clotting time afterward to determine the maintenance dose. Blood clotting time is generally maintained at 15 ~ 20 minutes or longer after use, but the dose is determined according to the case, indication, and purpose. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Before starting dialysis, administer 1,000 ~ 5,000 IU of heparin sodium; after starting dialysis, administer 500 ~ 1,500 IU per hour continuously, or administer additional doses of 500 ~ 1,500 IU intermittently every hour. (2) Regional heparinization: Administer 1,500 ~ 2,500 IU of this medication per hour continuously and neutralize with protamine sulfate during extracorporeal circulation. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU of this medication per kg of body weight, with additional doses as appropriate if the duration of extracorporeal circulation is prolonged. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the effects of heparin. 2. Intravenous drip infusion Dissolve 10,000 ~ 30,000 IU of this medication in 1,000 mL of 5 % dextrose injection, normal saline injection, or Ringer's solution, and infuse at approximately 30 drops per minute. When whole blood clotting time reaches 2 ~ 3 times the pre-administration value, continue the drip infusion at approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU of this medication intravenously every 4 ~ 8 hours. Starting 3 hours after the initial dose, measure whole blood clotting time every 2 ~ 4 hours and adjust the dose to maintain it at 2 ~ 3 times the pre-administration value. 4. Subcutaneous injection Administer 10,000 ~ 20,000 IU of this medication subcutaneously, followed by a maintenance dose of 15,000 ~ 20,000 IU every 12 hours. Use a different injection site each time to prevent hematoma formation. 5. Blood transfusion and blood tests For blood transfusion, usually use 400 ~ 500 IU of this medication per 100 mL of blood; for blood tests, use 100 IU per 20 ~ 30 mL of blood.

Ingredients

Manufacturer
BM Co., Ltd.

Efficacy & effects

Prevention and treatment of thrombotic and embolic diseases; diagnosis and treatment of coagulation disorders; inhibition of blood coagulation

  • Thrombosis
  • pulmonary embolism
  • embolic atrial fibrillation
  • coagulation disorders
  • blood coagulation
  • cerebral thrombosis
  • coronary artery occlusion
  • peripheral artery embolism
View approved original text

This medicine is used to prevent and treat blood coagulation in various situations related to thrombosis. It can prevent thrombosis or pulmonary embolism after surgery and is effective in the prevention and treatment of embolic atrial fibrillation. It also helps prevent blood coagulation during vascular and cardiac surgery, reducing postoperative complications. It is used for the diagnosis and treatment of acute and chronic coagulation disorders and can aid in preventing cerebral thrombosis caused by cerebral hemorrhage. Additionally, it is used to prevent blood coagulation during transfusions, extracorporeal circulation, and dialysis, as well as to treat coronary artery occlusion and peripheral artery embolism. Therefore, it effectively treats and prevents various conditions related to thrombosis.

How it is given

Adult administration

Usually administered by intravenous injection or added to the perfusate during extracorporeal circulation. The effect occurs immediately after administration, but heparin sensitivity varies considerably among individuals. Therefore, perform a heparin sensitivity test before administration and measure blood clotting time afterward to determine the maintenance dose. Blood clotting time is generally maintained at 15 ~ 20 minutes or longer after use, but the dose is determined according to the case, indication, and purpose. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Before starting dialysis, administer 1,000 ~ 5,000 IU of heparin sodium; after starting dialysis, administer 500 ~ 1,500 IU per hour continuously, or administer additional doses of 500 ~ 1,500 IU intermittently every hour. (2) Regional heparinization: Administer 1,500 ~ 2,500 IU of this medication per hour continuously and neutralize with protamine sulfate during extracorporeal circulation. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU of this medication per kg of body weight, with additional doses as appropriate if the duration of extracorporeal circulation is prolonged. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the effects of heparin. 2. Intravenous drip infusion Dissolve 10,000 ~ 30,000 IU of this medication in 1,000 mL of 5 % dextrose injection, normal saline injection, or Ringer's solution, and infuse at approximately 30 drops per minute. When whole blood clotting time reaches 2 ~ 3 times the pre-administration value, continue the drip infusion at approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU of this medication intravenously every 4 ~ 8 hours. Starting 3 hours after the initial dose, measure whole blood clotting time every 2 ~ 4 hours and adjust the dose to maintain it at 2 ~ 3 times the pre-administration value. 4. Subcutaneous injection Administer 10,000 ~ 20,000 IU of this medication subcutaneously, followed by a maintenance dose of 15,000 ~ 20,000 IU every 12 hours. Use a different injection site each time to prevent hematoma formation. 5. Blood transfusion and blood tests For blood transfusion, usually use 400 ~ 500 IU of this medication per 100 mL of blood; for blood tests, use 100 IU per 20 ~ 30 mL of blood.

Precautions

This drug is very potent, so it should only be used under strict medical supervision. Patients with diseases at high risk for bleeding should use caution, as bleeding can occur in almost any part of the body for patients who have received this drug. In rare cases, fatal bleeding may occur, and severe bleeding such as adrenal hemorrhage, ovarian hemorrhage, and retroperitoneal hemorrhage have also been reported. Additionally, benzyl alcohol present in this drug can cause severe respiratory issues in premature infants, so it should not be used in newborns and premature babies. Patients allergic to this drug or its components, patients with inappropriate results on blood coagulation tests, and patients with bleeding or at high risk of bleeding should not be administered this drug. Patients with severe liver or kidney diseases, those who have recently undergone central nerve system or eye surgery, and those who have received spinal or epidural anesthesia should also avoid use. While administering this drug, blood coagulation status should be regularly monitored, and if any signs of bleeding occur, use of the drug should be stopped immediately. Platelet counts should also be continuously monitored, and if a rapid decrease is found, administration should be discontinued. This drug can interact with other medications, so caution is needed when used in combination with acetylsalicylic acid or non-steroidal anti-inflammatory drugs, anticoagulants, and thrombolytics, as the risk of bleeding may increase. Pregnant or breastfeeding women should be particularly cautious due to the risk of bleeding in the uterus and placenta and during delivery, although it does not pass into breast milk, caution is still needed because of the benzyl alcohol component. Elderly patients or children should use this drug carefully as they may have an elevated risk of bleeding or the safety has not been established. In case of overdose, bleeding complications may occur, and if necessary, the antidote protamine sulfate should be used to neutralize it; the antidote must also be considered for potential side effects. During treatment, intramuscular injections should be avoided, and it is safe not to mix antihistamines and injections.

Side effects

  • Hemorrhage
  • fatal hemorrhage
  • acute adrenal insufficiency
  • adrenal hemorrhage
  • ovarian hemorrhage
  • retroperitoneal hemorrhage
  • cerebral hemorrhage
  • thrombocytopenia
  • arterial and venous thrombosis
  • acute reversible thrombocytopathy
Show 41 more
  • elevated γ-GTP
  • elevated LDH
  • elevated AST
  • elevated ALT
  • pruritus
  • urticaria
  • chills
  • fever
  • rhinitis
  • bronchial asthma
  • tear flow
  • conjunctivitis
  • cyanosis
  • tachycardia
  • feeling of pressure
  • angiogenic edema
  • nausea
  • vomiting
  • hypotension
  • dyspnea
  • bronchospasm
  • shock
  • alopecia
  • vitiligo
  • hemorrhagic necrosis
  • hypoaldosteronism
  • osteoporosis
  • rebound effect
  • dyslipidemia
  • inhibition of kidney function
  • localized painful hematoma
  • persistent erection
  • diabetes mellitus
  • hyperkalemia
  • hyperalkalemia
  • metabolic acidosis
  • elevated lipase
  • vascular spasm response
  • erythema
  • mild pain
  • ulcer

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container that protects it from light, at room temperature between 1 and 30 degrees Celsius. By storing it this way, the effectiveness of the drug can be maintained for a longer period.

Appearance and packaging

Appearance

A transparent liquid that is colorless or pale yellow, contained in a brown vial

Package unit

5mL/vial X 10 vials

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.